Coastlands Capital LP and related entities filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 852,669 shares of Sutro Biopharma, Inc. common stock, representing 5.14% of the outstanding class, as of a triggering event dated November 5, 2026.

Key Highlights

  • Beneficial ownership reported: 852,669 shares of Sutro Biopharma common stock (par value $0.001 per share), held directly by Coastlands Capital Partners LP.
  • Percent of class: 5.14%, calculated on a base of 16,581,171 shares outstanding as of August 7, 2026.
  • Voting and dispositive power: All 852,669 shares carry shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0 for all reporting persons.
  • Five reporting persons: Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry filed jointly but each disclaimed membership in a group.
  • Control person: Matthew D. Perry is identified as the control person of Coastlands, the Partnership, Coastlands GP, and the General Partner.
  • Date of triggering event: November 5, 2026, as stated on the filing cover.

Coastlands Capital's 5.14% Position in Sutro Biopharma: Filing Details

According to the Schedule 13G, five affiliated entities and individuals collectively reported beneficial ownership of 852,669 shares of Sutro Biopharma, Inc. (NASDAQ:STRO) common stock. The shares are described in the filing as held directly by Coastlands Capital Partners LP. Coastlands Capital LP serves as investment adviser to the Partnership, while Coastlands Capital GP LLC acts as the Partnership's general partner. Coastlands Capital LLC is identified as the general partner of Coastlands Capital LP, and Matthew D. Perry is described as the control person of all four entities.

The filing states that the percent of class, 5.14%, was calculated using 16,581,171 shares of common stock outstanding as of August 7, 2026, "as disclosed in the Quarterly Report on Form 10-Q filed by the Issuer on August 12, 2026." All five reporting persons report zero sole voting power and zero sole dispositive power over the 852,669 shares, with all voting and dispositive authority characterized as shared.

The filing notes that the reporting persons are filing jointly "but not as members of a group," and each disclaims beneficial ownership of the shares "except to the extent of that person's pecuniary interest therein." The filing further states that it "should not be construed as an admission" that Coastlands Capital Partners LP "is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any shares of Common Stock covered by this Schedule 13G." All reporting persons are organized under Delaware law, except Matthew D. Perry, who is a United States citizen. The business address listed for the reporting persons is 601 California Street, Suite 1210, San Francisco, CA 94108.

What Was Disclosed

Coastlands Capital LP and four related persons disclosed a combined 852,669-share position in Sutro Biopharma common stock, equal to 5.14% of the outstanding class, with all voting and dispositive power shared and none held solely by any single reporting person.